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The renal urothelium, the monolayered epithelium that
covers the papilla, is the direct target of increased pressure
during obstruction, yet most studies have mainly focused on
tubules, fibroblasts, and inflammatory cells. We studied this
epithelium in a unilateral ureteral obstruction mouse model
and found that it was disrupted and had broken tight
junctions, enlarged intercellular space, with loss of apical
uroplakins, and marginal lumen desquamation. Shortly after
obstruction these urothelial cells proliferated, peaking at
day 2. By day 14, the renal urothelium was transformed into
a multilayered barrier with newly synthesized uroplakins
including the de novo induction of uroplakin II. This
proliferation was found to be fibroblast growth factor (FGF)
dependent. Renal urothelial cells constitutively express the
FGF receptor 2, and obstruction activated the receptor by
phosphorylation. Treatment with FGF receptor 2-antisense or
vitamin A (an inhibitor of the MAP kinase in the FGFR2
pathway) decreased renal urothelial cell proliferation. Among
known FGF receptor 2 ligands, only FGF7 was upregulated.
Infusion of FGF7 into control mice caused the formation of a
multilayered structure at 7 days, resembling the urothelium
14 days following obstruction. Thus, the pressure/stretching
of renal monolayered urothelial cells is a very efficient trigger
for proliferation, causing the formation of a bladder-like
multistratified barrier with enhanced apical uroplakin
plaques. Presumably, this ensures efficient barrier protection
and repair.
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Obstructive nephropathy is an important cause of acute renal
failure, which may lead to end-stage renal disease or death.1
In experimental models, tubular dilatation, together with
tubular cell death and tubulo-interstitial injuries, shortly
occurs after unilateral ureteral obstruction (UUO). These
events are followed by fibroblast proliferation associated with
infiltrating inammatory cells, leading to massive interstitial
brosis within 2 weeks.2–4 Curiously, to our knowledge, no
study has been dedicated to the potential changes of
intrarenal urothelium during UUO, whereas this structure
is the first barrier subjected to stretching and hyperpressure.
In contrast to the bladder urothelium, a multilayered
structure submitted to pressure changes depending upon filling
or voiding states, intrarenal urothelium located near the
fornices is a monolayered structure,5–7 where no significant
stretching is believed to occur in physiological conditions.
Several studies suggest that the transient hyperpressure that
occurs within the bladder periodically accounts for special
phenotypic features in order to ensure an effective bladder.
Indeed, apical membranes of umbrella cells have high-resistance
tight junctions and are covered with specialized membrane
proteins, creating apical asymmetric plaques called uroplakins
(UPs), which contribute both to the physical strengthening of
the apical surface (with paired assembly between UPIII and Ib,
UPII and Ia being noteworthy) and apical membrane
permeability function at least for UPII and III.8–12 Furthermore,
whereas the proliferating index of urothelial cells is very low in
physiological conditions (0.1–0.5%),13 partial urethral outlet
flow induces a significant bladder urothelium proliferation,
leading to an increased layer thickness,14 strengthening the view
that adaptive changes to hyperpressure (and/or stretching) may
occur in order to preserve an efficient apical low-permeability
barrier to water and urinary solutes.
Our group has recently shown that renal urothelial cells
located near the fornices were unexpectedly the first contin-
gent to proliferate as soon as 18 h following renal ischemia–
reperfusion (IR) injuries in mice,6 therefore raising the issue
of the potential triggers at play, such as acidosis, hypoxia, or
stretching.
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Our present study shows that in UUO model hyperpres-
sure/stretching of renal monolayered urothelial cells is a very
efficient trigger for proliferation, leading to the onset of
bladder-like urothelium with a thick multilayered structure,
together with enhancement of apical UP plaques. Similar to
renal ischemia–reperfusion, fibroblast growth factor receptor
2 (FGFR2) activation appears as a critical step for urothelial
proliferation.
RESULTS
Intrarenal urothelium in normal kidney and after UUO
In normal kidney, the urothelium located in the deep cortex
at the corticomedullary junction is a monolayered barrier
(Figure 1a), with most urothelial cells staining positive for the
progenitor cell marker cytokeratin 14 (CK14; Figure 1b).
Conversely, in the bladder, urothelial cells constitute a
multilayered epithelium with only scattered basal CK14-
positive cells (Figure 1c and d). This barrier comprises at least
three different cell types: basal, intermediate, and apical
umbrella cells facing the urinary lumen (Figure 1c). Interest-
ingly, 14 days following UUO, intrarenal urothelium becomes
pluristratified (Figure 1e), with a very significant increase of
CK14-positive cell number at the basal side compared with
the mouse bladder urothelium (Figure 1f and d, respectively).
As shown by electron microscopy (Figure 1i), renal urothe-
lium cells are large and flattened monolayered cells with tight
junctions, lying upon a basement membrane and showing at
their apical side an underlined cell membrane, which at
higher magnification appear as asymmetric suggestive of UP
plaques (data not shown). Indeed, by immunochemistry,
apical staining for UP III is positive in normal renal urothelial
cells but also 14 days following UUO, characterizing an usual
urothelial phenotype (Figure 1g and h).
Proliferation of renal urothelial cells following UUO
Under physiological conditions, renal urothelial proliferation
assessed by KI67 index is o1%. At day 2 following UUO,
proliferation assessed by KI67 staining is detected in renal
urothelial cells lining the dilated urinary lumen (Figure 2a
and b), but also in some dilated tubules. Proliferation
occurs as early as 18 h following surgery, with an index of
23% by day 1 peaking to 33% by day 2 (Po0.01), as
shown Figure 2c (total number of urothelial cells ranging
from 32 to 62 per field). Whereas proliferation index is
decreased to B20% by day 3, a further inhibition down
to only 5% is observed in animals when ureteral clamps are
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Figure 1 |Bladder and renal urothelium structure in normal kidney and after unilateral ureteral obstruction (UUO). Paraffin-
embedded Masson’s trichrome staining microphotographs of normal renal urothelium near the (a) fornix, (c) normal bladder, and (e) renal
urothelium 14 days following UUO. (b) Immunostaining from frozen tissue sections for cytokeratin 14 in normal renal urothelium (brown),
(d) normal bladder, and (f) renal urothelium 14 days following UUO. Double staining with alkaline phosphatase–labeled anti-uroplakin III
(blue) in (g) normal renal urothelium and (h) urothelium 14 days following UUO. (i) Electron microscopy microphotograph of normal renal
urothelium. ‘þ þ ’ Indicates the basement membrane. Arrow indicates junctional complex. ‘*’ Denotes urinary space. Original
magnification: (b)  300; (a), (c), (d), (e), and (f)  400; (g), (h)  600; and (i)  25,000.
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removed at day 2 (Po0.05), together with a reduced urinary
tract dilatation (data not shown).
Whereas the renal urothelium appears as a continuous
structure in normal renal urothelium at low magnification, it
appears, by electron microscopy, partly disrupted in some
places at day 2 (with broken tight junctions) compared with
the normal urothelium (Figure 2e and d, respectively), with
small cuboidal cells lying on the basement membrane (Figure
2g), and the initiation of urothelial cells multilayer (H). It is
noteworthy that when ureteral clamps are removed at day 2,
the renal urothelium barrier is restored within 48 h as
demonstrated by a multilayered appearance (Figure 2i):
flattening of previously cuboidal cells, forming tiles slipping
one over the other, with reconstitution of ‘normal’ junctional
complexes and continuous underlined apical membrane
(Figure 2j and k) that were previously disrupted during a
blebbing process (Figure 2f).
Differentiation of renal urothelial cell phenotype
following UUO
As shown in Figure 3a, b, and c, renal urothelial cells express
UP III near the fornix area, whereas only scattered cells
(located mostly on the cortical side of urinary lumen) stain
positive for UP II with no detectable staining for UP Ia. By
day 2, urothelial cells have lost most of their apical membrane
UP (Figure 3d, e, and f). An intense secretion of vesicles in
the urinary lumen is responsible for the shedding of UPs
apical membranes, as suggested by electronmicroscopy data
(Figure 2f). However, by day 14, the newly formed urothelial
multilayer stained brightly positive for UP II and III but also
Ib (data not shown), whereas UP Ia staining remains
negative, which is in contrast to the urothelial bladder
epithelium (Figure 3g and i, respectively). Electron micros-
copy examination of the kidney at that time suggests a
strong UP expression in the apical urothelial membrane with
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Figure 2 |Proliferation and phenotype of the renal urothelium following unilateral ureteral obstruction (UUO). Anti-KI67
immunostaining in paraffin-embedded kidney sections at day 2 (D2) following UUO showing renal proliferation with (a) tubular
dilatation, (b) with a focus on urothelial cell proliferation (original magnification  400). Schedule of the urothelial proliferation index
following UUO (expressed as the percentage of Ki67-positive urothelial nuclei out of total urothelial nuclei count in a selected field).
(c) D2 þ 1 indicates removal of the clamp by D2 and assessment of proliferation index 1 day after. (d) Electron microscopy
microphotographs of the urothelium in normal kidney and (e) at D2 following UUO showing disruption of tight junctions and
enlargement of intercellular spaces, (f) loss of apical asymmetric membrane with blebbing processes, (g) urothelial proliferation with
cuboidal cells, and (h) in some places the initiation of the urothelial cell multilayer. Electron microscopy microphotographs of renal
urothelial cells 48 h after the removal of the surgical clamp (performed at D2 following UUO), showing (i) a multilayered barrier with
efficient junctional complexes and (j) de novo fusiform vesicles and (k) a continuous apical asymmetric unit membrane. Original
magnification: (a)  100; (b)  400; (g), (h), and (i)  5000; (d)  50,000; (j)  75,000; (e), (f)  100,000; and (k)  150,000. ‘þ ’ Indicates a
statistical difference (Po0.05) with KI67 index detected in basal conditions. ‘þ þ ’ Indicates a statistical difference (Po0.05) with KI67
index at D2 (n¼ 6 animals for each time point). Arrows indicate basement membrane. ‘**’ Indicates fusiform and discoidal vesicles, and
‘*’ denotes urinary space.
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reinforcement of asymmetrical plasma membrane, normal
tight junctions, and well-characterized fusiform cytoplasmic
vesicles containing UP, in addition to previously described
discoidal vesicles (Figure 2j).
Proliferation of urothelial cells following UUO is
mediated by FGFR2 activation
FGFR2, involved in the urothelial proliferative pathway, is
constitutively expressed in renal urothelial cells (Figure 4a),
with no phospho-FGFR-positive urothelial cells in control
kidney (Figure 4b). Following UUO, phospho-FGFR-positive
cells are detected within urothelial cells by 24 h (Figure 4d),
with the numbers increasing by 48 h (Figure 4e), together
with the presence of some positive tubular cells. Urothelial
positive staining by day 2 was abrogated when PFGFR
antibody was preincubated with a specific blocking peptide
(Figure 4f). A similar pattern, with a positive staining in
some renal urothelial cells (and also tubular cells), is observed
24 h after intraperitoneal (i.p.) FGF7 injection (Figure 4c).
Following UUO, although FGFR2 mRNA expression in
whole kidney extracts is not significantly modified (data not
shown), FGFR2 expression increases, evidenced by a 200-kDa
band most likely corresponding to FGFR2 dimers, together
with a decrease of the FGFR2 120-kDa band monomer
(Figure 4g). Consistent with FGFR2 activation through dimer
formation, phosphorylation of FGFR increases markedly
between baseline and day 2 (Figure 4h). Furthermore,
injection of FGFR2 antisense probe within the kidney at
the time of the surgery significantly inhibits renal urothelial
proliferation by 43% at day 2 (compared with animals
receiving scramble probe (Po0.001)) (Figure 4i). As shown
by western blot analysis, the amount of phospho-FGFR was
decreased by day 2 following UUO after antisense probe, but
not scramble, administration (Figure 4j). Among the three
known FGFR2IIIb ligands, FGF7 mRNA is significantly
increased in kidney extracts at day 2 (Figure 5a), whereas
FGF1 and FGF10 mRNA expression are not different (Figure
5b and c). As shown, i.p. administration of FGF7 in control
animals for 7 days induces an intense urothelial proliferative
response, transforming the urothelial monolayer (Figure 5d)
into a pluristratified urothelium (Figure 5e), which is similar
to what we observed at day 14 following UUO (Figure 1f or
1h). As a matter of fact, an intense urothelial cell proliferation
in kidney and bladder is detected 1 day after i.p. adminis-
tration of FGF7 in control mice as shown by 5-bromo-20-
deoxyuridine (BrdU) staining (Figure 5f and g). However, as
shown in Figure 5h and i, daily vitamin A i.p. infusion for 7
days before FGF7 administration markedly inhibits urothelial
cell proliferation at 24 h. Furthermore, as expected, vitamin A
pretreatment markedly inhibits UUO-induced urothelial
cell proliferation by 39% at day 1 and 59% at day 2
(P¼ 0.002 and 0.001 respectively), further supporting FGFR2
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Figure 3 |Modulation of uroplakin (UP) expression in renal urothelium following unilateral ureteral obstruction (UUO).
(a–c) Immunostaining from paraffin-embedded mouse kidney sagittal sections in control mice, (d–f) 2 days after UUO, and (g–i) 14 days
after UUO using (a, d, and g) anti-UPIa, (b, e, and h) anti-UPII, and (c, f, and i) anti-UPIII antibodies. Expression of (j) UPIa, (k) UPII, and (l) UPIII
in normal mouse bladder. Original magnification:  400. Microphotographs are representative of at least six animals for each time point.
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involvement in this process. Finally, daily administration of
erlotinib (a tyrosine kinase inhibitor) beginning 2 days before
UUO does not significantly inhibit urothelial cell prolifera-
tion index by day 2 (31.4% vs. 32.9% in untreated animals,
NS), ruling out activation of the EGFR pathway.
DISCUSSION
We show here that, following UUO, renal urothelium
proliferates intensively, leading to a ‘bladder-like’ pluristra-
tified barrier. Bladder urothelium is a multilayer composed of
basal cells located immediately on the basement membrane,
i.e., intermediate cells, whose number depends on the filling
state of the bladder and on large (25–250 mm) highly
differentiated cells called ‘umbrella cells’.15,16 These latter
cells possess an asymmetric unit membrane at their apical
side, the major constituents of which are a family of
transmembrane proteins called UPs,17,18 which form a two-
dimensional crystal contributing, together with junctional
complex, to a high-resistance permeability property of
urothelium to water and solutes, thus preventing rupture of
membranes during the filling phase of the bladder.19,20
In contrast to the bladder, the renal urothelium is
heterogenous depending on the location within the kidney: a
monolayered cuboid epithelium covering the renal papilla with
no UPs expression, and a single or two-layered epithelium in
the cortico-medullary area7 with strong UPIII and Ib staining,
fainted UPII, and no detectable UPIa staining. Despite the lack
of UPIa/II expression in the renal urothelium near the fornix,
UPIb/UPIII appears as an effective barrier to water and
solutes, as suggested by the asymmetric unit membrane
pattern detected by electron microscopy, with the outer leaflet
twice as thick as the inner leaflet.
Following UUO, renal urinary spaces and some tubules are
dilated, a consequence of the increased pressure due to the
clamping of the ureter. This increased pressure in the pelvi-
calyceal cavities exerts most likely a stretch on the urothelial
structure, which in some cases is responsible for the
enlargement of intercellular spaces, tight junction disruption,
and/or, in more severe cases, desquamation leading to
basement membrane denudation (data not shown). Ob-
viously, these severe lesions may account for an increased
permeability of the urothelial structure. Furthermore, within
day 1 or 2 after clamping, urothelial cell exocytosis activity is
intense, with loss of asymmetric unit membrane and UPs
staining, a process that may further account for an increased
permeability of the renal urothelial structure.21
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Figure 4 | Involvement of the fibroblast growth factor receptor 2 (FGFR 2) pathway following unilateral ureteral obstruction (UUO).
(a) Urothelial expression of FGFR2 (brown staining) in a normal mouse kidney (sagittal section from frozen tissue). Anti-phospho-FGFR
immunostaining in paraffin-embedded mouse kidney sagittal sections in (b) control mice, (c) at 24 h after intraperitoneal (i.p.) FGF7
administration, (d) on day 1 (D1), and D2 (e) without and (f) with a specific blocking peptide. Western blot analysis showing FGFR2
expression in whole kidney extracts obtained at days 0,1, and 2 following UUO. (g) An FGFR2 dimer 200-kDa band increase is detected
between D0 and D2, together with a slight decrease of the FGFR2 monomer 120-kDa band. (h) Western blot analysis from total kidney
extracts showing a significant phosphorylation of FGFR between D0 and D2 following UUO (n¼ 2 animals for each time point). (i) The effect
of FGFR2 anti-sense probe (AS) and scramble probe (S) on urothelial proliferation expressed as percentage of KI67 index at D2 following
UUO. AS and S probe were injected within the kidney at the time of surgery (n¼ 5 mice for each time point). (j) Western blot analysis of
FGFR phosphorylation from total kidney extracts at D2 following UUO after AS probe and S probe administration. Western blotting for actin
was used as a control. The asterisk denotes urinary space (flattened owing to the processing of frozen tissue in (a)). Original magnification:
(a)  200; and (b), (c), (d), (e), and (f)  600. A, artery; V, vein.
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Simultaneously to urothelial cell dedifferentiation, des-
quamation, and/or death, an intense early proliferation is
detected with a peak at day 2 (proliferation index up to 33%).
Dividing cells are cuboids, lying on the basement membrane
with no asymmetric unit membrane and no discoid vesicles.
It is noteworthy that in experimental settings where the
ureteral clamp is removed at day 2 urothelial cell prolifera-
tion is then sharply inhibited on the following day, and
within 2 days the urothelium is transformed into a
pluristratified structure with enlarged cytoplasmic expan-
sions covering neighboring cells as ‘flattened tiles’, narrow
intercellular spaces with efficient tight junctions, and
desmosomes. It is noteworthy that a similar pattern is
observed by day 14 following the natural history of UUO
(i.e., when the clamp is not removed), with re-expression of
UPIII/UPIb and also strong UPII staining (compared with
normal kidney), although no de novo UPIa expression is
detected. At day 2 after clamp removal, the asymmetric unit
membrane covers the entire apical membrane surface and
appears thickened (Figure 2k) with the abundance of
fusiform and discoid vesicles (Figure 2j), suggesting a
renewed and even more efficient barrier to water and solutes
compared with normal basal conditions.
Within the kidney, most urothelial cells express CK14, in
contrast to the bladder where CK14-positive epithelial
progenitors are scattered along the basement membrane.22
In a previous study, we demonstrated that proliferation of
CK14-positive urothelial cells was occurring shortly after
renal ischemia, in accordance with the expectation of
progenitor cells.6 Several lines of evidence suggest that these
cells that constitutively express FGFR2 do proliferate under
the control of the FGFR2 pathway. Indeed, phospho-FGFR is
detected in several renal urothelial cells following UUO or
FGF7 administration (a known specific FGFR2IIIb ligand),
leading in both cases to urothelial cell proliferation, whereas
phospho-FGFR is not detected in the non-proliferating
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Figure 5 | Fibroblast growth factor 7 (FGF7)/FGF receptor 2 (FGFR2) involvement in renal urothelial cell proliferation. Quantitative
real-time polymerase chain reaction (RT-PCR) from kidney extracts obtained at days 0, 1, and 2 following unilateral ureteral obstruction
(UUO; n¼ 6 for each time point) for (a) FGF7, (b) FGF1, and (c) FGF10. Results are expressed as % from baseline (day 0).
(d) Microphotographs showing cytokeratin 14 staining in renal urothelial cells from normal mouse kidney (paraffin-embedded tissue) and
(e) after a 7-day administration of FGF7 (intraperitoneal, i.p.) in control animals. Immunofluorescence microphotographs of 5-bromo-20-
deoxyuridine (BrdU) staining 24 h after a single administration of FGF7 (i.p.) in (f) control mouse kidney and (g) bladder or with a vitamin A
pretreatment (daily i.p for 7 days) before FGF7 administration in the (h) kidney and (i) bladder (frozen sections, original magnification
 600). BrdU was added in the drinking water from day 0 (original magnification  200). (j) Effect of vitamin A pretreatment for
7 days before UUO on urothelium proliferation, as assessed by the KI67 index. ‘þ ’ Indicates a statistical difference (Po0.05)
between vitamin A–treated and non-treated animals (n¼ 6 animals for each time point). The asterisk denotes urinary space. Original
magnification: (d), (e)  600; and (f), (g), (h), and (i)  200.
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normal urothelium. Moreover, vitamin A pretreatment,
reported previously to inhibit the MAP kinase–dependent
FGFR2 pathway,23–25 has the expected inhibiting effect on
urothelial cell proliferation following both UUO and FGF7
administration. Similarly, FGFR2 antisense administration,
which blocks FGFR2 mRNA expression, induces a marked
decrease in the amount of phosphorylated FGFR2 by day 2 in
whole kidney extracts, together with a significant decrease of
the urothelium proliferation index. Finally, FGF7 infusion in
control mice for 7 days induces urothelium pluristratification
with a pattern very similar to the renal urothelium at day 14
following UUO with basal CK14-positive cells. As a matter of
fact, our data are in accordance with previous reports
showing an FGFR2-mediated bladder urothelium prolifera-
tion both in vitro and in vivo,26,27 as well as an FGF-7-
dependent bladder pluristratification (FGF7 knockout mice
lacked the intermediate cell layer).28
Following UUO, FGFR2 activation occurs not only in
urothelial structure but also in other renal structure
noteworthy tubules that constitutively express FGFR229 as
suggested by the increased FGFR2 dimer band in western
blots from whole kidney extracts following UUO. It is thus
tempting to speculate that FGFR2 activation could be a
critical event following UUO, not only in the renal
urothelium but also in other renal structures such as tubular
cells as previously reported.30
However, in contrast to bladder urothelium and renal
tubules, renal urothelium proliferates independently to the
EGFR pathway, as tyrosine kinase inhibitor or EGF admin-
istration did not modulate renal urothelium proliferation
(data not shown). Moreover, among the three known ligands
of FGFR2, only FGF7 was upregulated following UUO,
similar to the renal ischemia–reperfusion model,6 whereas in
the bladder FGF7 together with FGF10 appears operative.14
Our data, however, do not rule out a potential role of FGF10
from an extrarenal sourcing.
Our results thus raise several issues: (1) the short lag time
period between urothelium lesions and repair, which suggests
that urothelium high-resistance permeability barrier could be
a critical event for kidney repair and potentially renal tissue
protection; (2) alternatively, urothelial cell proliferation in
response to increased stretching and/or hypoxia could be
deleterious on renal tissue. A paracrine secretion of cytokines
and inflammatory mediators including inducible nitric oxide
synthase, as shown in the bladder, could initiate and foster
renal inflammation and ultimately interstitial fibrosis.31
Further studies are warranted to address this important issue.
In conclusion, ureteral obstruction exerts on the renal
urothelium an adaptative process that transforms the
urothelium monolayer into a ‘bladder-like’ structure pre-
sumably to ensure an efficient barrier repair.
MATERIALS AND METHODS
In vivo experiments
All in vivo experiments were conducted on female
C57BL/6 mice weighing between 20 and 25 g. Animal
handling was performed according to the French ethical
committee Charles Darwin recommendations and under the
supervision of authorized investigators. Surgery was perfor-
med under general anesthesia after i.p. injection of the com-
bination of ketamine 100mg/kg and xylazine 20mg/kg.
The left ureter was visualized following a midline
abdominal incision, and occlusion was performed using a
vascular clamp (Roboz Surgical Instrument, Gaithersburg,
MD). Sham mice underwent the same procedure, except that
the ureter was not clamped. As indicated below, mice were
killed at different time points following surgery. In some
experiments, surgical clamps were removed by day 2, and
kidneys were analyzed further as indicated.
BrdU was added in the drinking water (Sigma, Saint-
Quentin Fallavier, France, 0.8mg/ml) after surgery in order
to assess cell proliferation. Intraperitoneal injection of FGF7
(Palifermin, Swedish Orphan Biovitrum, Stockholm, Sweden,
60 mg/kg) was administrated once or daily as indicated in
control mice. A specific FGFR2 antisense oligonucleotide
phosphorothioate (50-TGTTTGGGCAGGACAGTGAGCCA-30)
designed to hybridize the 30 region of FGFR2 mRNA pro-
moter30 and a scrambled oligonucleotide used as a control
were injected into the kidneys at the time of surgery, as
previously described (112 mg/kg diluted in NaCl 0.9%).
In some experiments, erlotinib (Roche, Neuilly-sur-Seine,
France), a tyrosine kinase antagonist, was given daily (2 mg/g,
p.o.), starting 2 days before UUO, until the time of killing.
Kidneys and bladders were collected and snap-frozen in
liquid nitrogen or paraffin embedded for subsequent analysis
as indicated.
Immunohistochemistry
Kidneys were isolated and cut in a sagittal axis from the
convexity to the pedicle as previously described.6 The
following primary antibodies were used: anti-Ki67, anti-
Collagen IV (Abcam, Paris, France), anti-Cytokeratin 14
(Covance, Rueil-Malmaison, France), anti-UPIa, UPIb, UP
II, UP III, and anti-FGFR2 (Santa Cruz Biotech, Santa Cruz,
CA). Monoclonal FITC-labeled anti-BrdU antibody was
purchased from BD Biosciences (San Jose, CA). Polyclonal
anti-phospho-FGFR (directed against Y653/654 present in
Phospho FGFR1 and 2) and its specific blocking peptide were
purchased from Abgent (San Diego, CA).
The following secondary peroxidase-labeled polyclonal
antibodies were used: goat anti-mouse, rat anti-mouse,
and rabbit anti-mouse immunoglobulin, all obtained
from Histofine Incorporated (Tokyo, Japan). For double-
labeling sections, avidin–biotin coupling secondary
polyclonal antibodies using alkaline phosphatase technique
(Vector Blue Alkaline Phosphatase Substrate Kit III, Eurobio-
AbCys, Les Ulis, France) were used.
Urothelial proliferation index was assessed by the ratio of
Ki67-positive urothelial nuclei out of the total number of
urothelial nuclei in a selected field (magnification  400).
The mean value was calculated from 10 selected fields per
kidney (n¼ 6 animals for each experiment).
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Electron microscopy
Electron microscopy was performed for mouse bladder and
kidney tissues. Tissues were fixed in cold 2.5% glutaraldehyde
per 0.1mol/l cacodylate buffer, pH 7.2, postfixed in 1%
osmium tetroxide per 0.1mol/l cacodylate buffer, dehydrated in
alcohol, and embedded in epoxy resin EMbeb-812 (Euromedex,
Mundolsheim, France). Semithin sections were stained with
toluidine blue and examined by light microscopy to identify
regions of the blocks containing the urothelial structures.
Ultrathin sections were stained with uranyl acetate and lead
citrate, and were examined with a Jeol 1010 Transmission
Electron Microscope (Jeol Europe, Croissy sur Seine, France).
Western blot analysis
The kidney tissue samples were homogenized in RIPA buffer
and subjected to electrophoresis. After electrophoresis on
NuPAGE Novex Bis-Tris Mini Gels (Invitrogen, Saint Aubin,
France), proteins were transferred to the nitrocellulose
membrane (Immobilon-p, Millipore, Billerica, MA). Non-
specific antibody reaction was blocked by incubating the mem-
brane in PBS-Tween solution with milk powder (5%). Western
blotting was performed using goat polyclonal anti-Bek (P-17,
FGFR2) antibody (Santa Cruz Biotech) and rabbit polyclonal
antibody to b-actin (Imgenex, San Diego, CA).
Real-time polymerase chain reaction analysis
Total RNA was extracted from the kidney using TRIzol
solution (Gibco BRL, Saint Aubin, France) and methyl
trichloride. By using a reverse transcriptase (Superscript II,
Gibco BRL), cDNA was obtained from 1 mg RNA and
amplified in a thermocycler (ABI Prism 7000, Life Technol-
ogies SAS, Villebon-sur-Yvette, France) by using a Quantitect
Probe PCR Kit (Qiagen, Courtaboeuf, France) and TaqMan
Gene expression assays (Life Technologies SAS): TaqMan
MGB probes, FAM dye-labeled fgf r2 (Mm01269930_m1),
fgf 1 (Mm01258325_m1), fgf 7 (Mm00627025_g1), fgf 10
(Mm01297079_m1) and b-actin (Mm02619580_g1) for
normalization. Normal kidney cDNA was used as reference
to establish calibration curves of genes of interest (GOI) and
b-actin cycle threshold. Results are expressed as the GOI/b-
actin cDNA ratio.
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